Dr. Reddy's Laboratories Limited announced the FDA approval of the ANDA for allopurinol oral products, positioning the company to expand its established market presence in the xanthine oxidase inhibitor segment. This action enhances Dr. Reddy's portfolio in chronic gout management and increases competitive pressure on branded generics in established indications.